Abstract
Objective The objective of the study was to confirm the efficacy and safety of Astodrimer 1% Gel to prevent recurrence of bacterial vaginosis.
Study Design 864 women with a diagnosis of bacterial vaginosis and a history of recurrent bacterial vaginosis were enrolled in North America and first received oral metronidazole (500 mg twice daily for 7 days). Women successfully treated with metronidazole were randomly assigned 1:1 to Astodrimer 1% Gel (N=295) or placebo (N=291) at a dose of 5 g vaginally every second day for 16 weeks, and followed for a further 12 weeks off-treatment. The primary endpoint was recurrence of bacterial vaginosis (presence of ≥3 Amsel criteria) at or by Week 16. Secondary endpoints included time to recurrence, and recurrence of subject-reported symptoms. Adverse events were monitored throughout the study.
Results Astodrimer 1% Gel was superior to placebo for the primary and many secondary efficacy measures. At or by Week 16, bacterial vaginosis recurred in 44.2% (130/294) of women receiving astodrimer and 54.3% (158/291) receiving placebo (P=.015). Time to recurrence of bacterial vaginosis was significantly longer for women receiving astodrimer compared with placebo (Kaplan-Meier survival curves, P=.007). Recurrence of subject-reported symptoms at or by Week 16 was also significantly lower in the astodrimer arm compared with placebo (vaginal odor and/or discharge, 27.9% [75/269] vs 40.6% [108/266], P=.002). A significantly lower proportion of patients receiving astodrimer compared with placebo had recurrence of bacterial vaginosis at or by Week 16 by other secondary measures, including individual Amsel criteria (vaginal discharge and clue cells) and Nugent score 7-10. Recurrence of subject-reported vaginal odor and/or discharge was significantly lower in the astodrimer arm compared with placebo up to 8 weeks after cessation of therapy (36.1% [97/269] vs 45.5% [121/266], P=.027).
Adverse events were infrequent, and rates were generally similar between placebo and astodrimer groups. Vulvovaginal candidiasis and urinary tract infection occurred more often in women receiving astodrimer.
Conclusions Astodrimer 1% Gel, administered every second day for 16 weeks, was effective and superior to placebo for prevention of recurrent bacterial vaginosis in women with a history of recurrent BV, and was well-tolerated.
- Astodrimer Gel
- bacterial vaginosis
- biofilm
- prevention
- recurrent bacterial vaginosis
- SPL7013
- VivaGel
Competing Interest Statement
JRS is a paid consultant for Starpharma Pty Ltd, Talis One, Toltec, Lupin Pharmaceuticals, and Hologic. ASW received research funding from Gage Development Company.
Clinical Trial
NCT02237950
Funding Statement
This study was funded by Starpharma Pty Ltd. Starpharma Pty Ltd was responsible for the study design, the collection, analysis and interpretation of data, the decision to submit the article for publication, and preparation of the manuscript. The funder provided support in the form of research funding for this study to JRS, BAC and ASW. The funder provided support in the form of salaries for JRAP, CFP and AC, and consulting fees for KJA, PMcC and GRK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by an institutional review board, Quorum Review, Inc., on June 20, 2014.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Statement: JRS is a paid consultant for Starpharma Pty Ltd, Talis One, Toltec, Lupin Pharmaceuticals, and Hologic. ASW received research funding from Gage Development Company.
Financial Disclosure Statement: This study was funded by Starpharma Pty Ltd. Starpharma Pty Ltd was responsible for the study design, the collection, analysis and interpretation of data, the decision to submit the article for publication, and preparation of the manuscript. The funder provided support in the form of research funding for this study to JRS, BAC and ASW. The funder provided support in the form of salaries for JRAP, CFP and AC, and consulting fees for KJA, PMcC and GRK.
Clinical Trial Registration: Date of Registration: September 12, 2014; First Patient Enrolled: October 13, 2014; Identification No.: NCT02237950; clinicaltrials.gov
Paper Presentation: The 46th Annual Meeting of The Infectious Diseases Society for Obstetrics and Gynecology (IDSOG), Big Sky, Montana, USA, August 8-10, 2019
Condensation This phase 3 randomized controlled trial demonstrated efficacy and safety of Astodrimer 1% Gel for the prevention of recurrent bacterial vaginosis.
Manuscript word count reduced, reformatting.
Data Availability
The data that support the findings of this study are available from the corresponding author (JRAP) upon reasonable request.
